Form D · Pharmaceuticals
Curzion Pharmaceuticals, Inc.
San Diego, CA · CIK 0001782353
Offering snapshot reported Jul 15, 2019 · SEC filing
- Reported sold
- $3.5M Offering amount: $3.5M
- Investors reported
- 8 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Mar 26, 2019 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jul 15, 2019 | Initial | $3,500,000 | No comparison | 8 | SEC filing |
Offering details
- Securities
- Equity, Debt, Option to acquire, Security to be acquired
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-344286
Source: Form D, filed Jul 15, 2019. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Susan Dube | Executive |
| Mike Grey | Director, Executive |
| Johan Kordel | Director |
| Ed Mathers | Director |
| Niall O'donnell | Director |
| Kyle Rasbach | Director |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
12230 El Camino Real Suite 230
San Diego, CA, 92130
San Diego, CA, 92130